Proton therapy continues to be a promising modality for the treatment of head and neck cancers, and several recent studies ...
In final draft guidance (PDF), NICE has said that Keytruda (pembrolizumab) can be used within NHS England as a treatment for ...
Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...
Hosted on MSN
Many head and neck cancer trials end early. Why?
Head and neck cancer trials are frequently derailed before they can deliver answers. A new analysis suggests that the most common reasons are sponsor decisions related to safety or effectiveness and ...
April marks Head and Neck Cancer Awareness Month, a national campaign encouraging early detection and raising awareness of ...
The visual nature of head and neck cancer calls for treatment strategies that will minimize toxicities related to radiation therapy. Advances in precision radiation techniques, supportive care, and ...
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...
Strasbourg, France & Schiphol, Netherlands, April 2, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs ...
Head and neck cancer trials are frequently derailed before they can deliver answers. A new analysis suggests that the most common reasons are sponsor decisions related to safety or effectiveness and ...
Advanced disease stage was the strongest predictor of high first-year healthcare costs in Canadian patients with head and neck cancer, a recent analysis found. Patients with stage IV disease had an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results